Our Therapeutic Areas
The cornerstone of our research into new medicines is focused on those disease areas where we have built significant expertise over time. We are concentrating our research efforts and investment in these key therapeutic areas: CardioMetabolic diseases; Central Nervous System diseases; Immunology and Respiratory diseases; and Oncology and Cancer Immunology.
CardioMetabolic Disease Research
Boehringer Ingelheim sets the bar high for innovation in cardiometabolic diseases. We have a strong legacy of ‘firsts’, extending over many decades, which have revolutionized the treatment landscape. Most recently this includes empagliflozin which is the first type 2 diabetes treatment approved to reduce cardiovascular death* in patients with type 2 diabetes and established cardiovascular disease. But our scientists are also looking to the future and examining their research through a new lens to investigate the next generation of breakthrough medicines for patients.
* Approved by the US FDA
-
Working together in CardioMetabolic Diseases
Therapeutic Areas
-
Therapeutic Areas